logo
Researchers Claim Ancient Chinese Star Catalog Is the Oldest of Its Kind—But Not Everyone's Convinced

Researchers Claim Ancient Chinese Star Catalog Is the Oldest of Its Kind—But Not Everyone's Convinced

Gizmodo24-05-2025

Humans have been stargazing for thousands—possibly hundreds of thousands of years. Ancient people around the globe looked to the heavens for physical and spiritual guidance. Dozens and dozens of generations later, their descendants are now arguing over which civilization created the oldest known visual star catalog in the world.
Researchers from the Chinese Academy of Sciences' National Astronomical Observatories claim that Shi's Star Catalog, the oldest known star catalog in China, is actually the earliest known star catalog, period. They reached this conclusion using a technique that accounts for potential human errors made thousands of years ago. If their results prove to be true, it would mean that Shi's Star Catalog is centuries older than the other first place contender—the one created by Greek astronomer Hipparchus. But not everyone in the scientific community is convinced.
'In comparison to the observation epochs of other ancient star catalogs worldwide, the Shi's Star Catalog predates even the oldest Western star catalogs, affirming its status as the oldest star catalog in the world,' the researchers wrote in a study posted to the preprint server arXiv in April.
Because Earth's axis wobbles, the location of stars in the night sky changes over the centuries in a phenomenon called precession. Researchers can use Earth's precession to date ancient visual star catalogs by calculating the difference between historical records of the night sky and what our stars look like now.
Shi's Star Catalog, however, has been infamously difficult to date, not least because this one catalog depicts star positions that seem to span multiple centuries. In the preprint study, the researchers outline a number of previously suggested dates: around 360 BCE; around 360 BCE with an update around 200 CE; around 440 BCE with an update around 160 CE; sometime between 100 BCE and 70 BCE; and during the seventh century CE.
'A multitude of perspectives exist regarding the observational timeframe of the Shi's Star Catalog, with no definitive consensus reached,' the researchers admitted. As such, they decided to analyze the catalog's 120 stars with the Generalized Hough Transform method—an algorithmic imaging technique that 'statistically accommodates errors in ancient coordinates and discrepancies between ancient and modern stars, addressing limitations in prior methods,' they explained. This approach seems to confirm that Shi's Star Catalog was first drafted around 355 BCE and then updated around 125 CE.
'In comparison, the Western tradition's oldest known catalog, the Ptolemaic Star Catalog (2nd century CE), likely derives from the Hipparchus Star Catalog (2nd century BCE). Thus, Shi's Star Catalog is identified as the world's oldest known star catalog,' they added.
Some scientists, however, have a different theory: The instrument used to record Shi's Star Catalog was off by one degree. Previous studies adjusting for this assumption date Shi's Star Catalog around or after 103 BCE, as reported by Science. Certain historians look favorably on this later date because it aligns the catalog's use of spherical coordinates more closely with the Chinese invention of the armillary sphere (a spherical mathematical instrument used to track the movement of celestial bodies around Earth) and their adoption of a spherical cosmological model, both of which took place in the first century BCE, according to Science.
Suggesting that people used spherical coordinates hundreds of years before the invention of the armillary sphere, as the researchers do in the recent study, would be like finding 'a receipt from a gas station and somebody wants to say it's from 1700,' Daniel Patrick Morgan, a historian at France's Center for Research on East Asian Civilizations who was not involved with the study, told Science.
Future research may provide more answers. Whether or not the recent study proves to be true, it's worth noting that the Western world's Eurocentric approach has historically undervalued achievements made elsewhere, including those in ancient China. Plus, the ancient Babylonian seventh century BCE Astronomical Diaries blow both European and Asian astronomical artifacts out of the water, even though the tablets list astronomical observations via text, not visuals.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Remission, Attaining CV Risk Targets Drops CVD Risk in Lupus
Remission, Attaining CV Risk Targets Drops CVD Risk in Lupus

Medscape

time2 hours ago

  • Medscape

Remission, Attaining CV Risk Targets Drops CVD Risk in Lupus

Patients with systemic lupus erythematosus (SLE) had more than double the risk for atherosclerosis progression over 10 years than healthy control individuals, but maintaining cardiovascular risk factor (CVRF) targets and achieving sustained disease remission significantly reduced this risk. METHODOLOGY: Researchers collected carotid ultrasound measurements from 111 patients with SLE and 94 age- and sex-matched controls, including baseline measurements from 2012 to 2013 with follow-up assessments at 3, 7, and 10 years. They tracked carotid plaque progression, CVRF target attainment on the basis of the 2016 European Society of Cardiology Guidelines on cardiovascular disease (CVD) prevention and additional CVD risk modifiers, and incident CVD events over 10 years and looked for predictors of plaque progression. TAKEAWAY: Patients with SLE demonstrated a 2.3-fold higher risk for carotid plaque progression than healthy control individuals (incidence rate ratio [IRR], 2.26; 95% CI, 1.34-3.81; P = .002). = .002). Each CVRF maintained at target during the 10-year follow-up reduced plaque progression risk by 32% (IRR, 0.68; 95% CI, 0.53-0.89; P = .004). = .004). Achievement of definition of remission in SLE for ≥ 75% of follow-up decreased risk for plaque progression by 43% (IRR, 0.57; 95% CI, 0.34-0.95; P = .033). = .033). Persistent triple antiphospholipid antibody positivity increased 10-year risk for incident cardiovascular events in SLE more than sevenfold (hazard ratio, 7.52; P = .014). IN PRACTICE: 'Patients with SLE experience a 2.3-fold higher 10-year atherosclerosis progression risk than [healthy controls], which is significantly mitigated by sustained [cardiovascular risk factor] control and prolonged clinical remission,' the study authors wrote in the abstract. 'Carotid ultrasound may have an additive role in enhancing CVD risk assessment in patients with SLE.' SOURCE: Maria G. Tektonidou, MD, PhD, of the National and Kapodistrian University of Athens, Athens, Greece, presented the study at the 16th International Congress on Systemic Lupus Erythematosus in Toronto. LIMITATIONS: The study sample was relatively small. Carotid ultrasound is dependent on operator skill and experience, which can lead to interobserver and intraobserver variability. DISCLOSURES: Funding information for this research was not provided. Disclosure information for the authors was not available.

China's Coal Industry Has a Big, Dirty Secret
China's Coal Industry Has a Big, Dirty Secret

Bloomberg

time6 hours ago

  • Bloomberg

China's Coal Industry Has a Big, Dirty Secret

Exactly a century ago, two German chemists patented a process to transform coal into liquid fuels. Following its discovery in 1925, the Fischer-Tropsch synthesis eventually became infamous: The Nazis used it to fuel their war machine, and apartheid South Africa turned to it to offset the impact of an oil embargo in the 1980s. Its last — and huge — user is China. Largely unnoticed, the size of this obscure corner of the Chinese coal industry has reached gargantuan proportions: It consumes about 380 million metric tons of coal as a feedstock for chemical and liquid fuel production, according to the International Energy Agency. To understand its size better, it helps to think about the segment as if it were a country. As such, it would rank as the world's third-largest consumer, only behind the rest of the Chinese coal sector and India, but ahead of the US, Japan and other top coal-consuming nations like Indonesia and Turkey. It's not a little dirty secret — it's a big one, with significant implications for global climate and energy policy. The longer China remains addicted to coal, the more difficult it will be to decrease carbon dioxide emissions. Despite its huge progress in green energy, from electric cars to solar panels, the Asian giant consumes more coal than every other country on the planet combined. Crucially, the Chinese coal-conversion industry is set to expand even further, potentially offsetting declines elsewhere in the country, including a reduction in coal demand to produce cement and steel. 'We expect a growth between 5% and 10% in the coming years,' Carlos Fernandez Alvarez, head of coal at the IEA, tells me. Unfortunately, the sector is a black hole, as China publishes scant statistical information about it. For decades, China has converted some of its coal into chemical products and liquid fuels in what scholars call the 'traditional' coal chemical industry. The starting point was almost always metallurgical coal, converted into coke, and further transformed into ammonia-based fertilizers and acetylene-based chemicals. Yet over the last two decades, China has built a second layer, typically referred to as the 'modern' coal chemical industry, based on new variations of the old Fischer-Tropsch process plus sophisticated new methods, including methanol synthesis to produce petrochemical goods, such as olefins, used in turn to make plastics. The modern part of that processing was largely experimental in the early 2000s. Commercial-scale projects mushroomed in the 2010s, and, after a brief hiatus, more have emerged in recent years, particularly in the Chinese heartland, where the bulk of the country's coal fields are located far from coastal cities. By now, its scale — which dwarfs all other countries' coal-to-chemicals production — and growth is surprising even veteran industry observers. Look at some modernized plants and coal is nowhere to be seen: It's mined underground almost directly beneath the chemical facilities, carried by conveyor into the furnaces where it's gasified and transformed. From there, it goes into your plastic water bottle or synthetic fabric clothes. 1

Latest Data of InnoCare's Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
Latest Data of InnoCare's Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting

Associated Press

time7 hours ago

  • Associated Press

Latest Data of InnoCare's Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting

BEIJING--(BUSINESS WIRE)--Jun 1, 2025-- Latest data of InnoCare's robust oncology pipelines were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Oral Presentation Title: Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL) (Abstract No.: 2514) The current study is the first and only report on the preliminary efficacy data of anti-CCR8 targeted therapy for CTCL patients. The efficacy of ICP-B05 was supported by the PD effects in both skin lesions and peripheral blood in the depletion of CCR8+ cells. ICP-B05 is safe and well tolerated and its safety profile made it a good candidate for combo therapies for CTCL patients with lymph node and other organ involvement. As of Jan. 6, 2025, a total of 13 patients with R/R CTCL were treated. There were 12 patients received at least one skin lesion assessment followed the mSWAT. 33.3% of patients achieved PR, and 58.3% of patients were assessed as SD with reduction in skin lesion. The 6-month PFS rate was 82.5%, and the median PFS was 11.4 months. Among the five patients with CCR8+ levels exceeding 10%, four (80%) achieved PR. PK analysis showed that serum exposure (Cmax and AUC0-14D) increased with dose escalation. PD analysis demonstrated significant depletion of CCR8-expressing cells in CTCL skin lesions. Poster 1: Title: Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies (Abstract No.: 7038) The results of ICP-248 monotherapy suggests a well-tolerated safety profile and an exciting efficacy in BTK failed, heavily treated, relapsed or refractory B-cell malignancies. As of April 15, 2025, a total of 68 patients were enrolled in the dose escalation and dose expansion study. 17 R/R CLL/SLL and 32 R/R MCL patients were treated with 125 mg of ICP-248, including 10 CLL/SLL and 25 MCL patients were previously treated with BTK inhibitors, and 70.0% of CLL/SLL patients and 100% of MCL patients were resistant to BTK inhibitors. 17 CLL/SLL and 26 MCL patients had at least one response assessment. Among the BTK naïve patients, the ORR for R/R CLL/SLL and R/R MCL patients were both 100%, and the CRR was 14.3% and 71.4% respectively, of which 43% of MCL patients reported undetectable minimal residual disease (uMRD). Among the BTK treated patients, the ORR for R/R CLL/SLL and R/R MCL patients were 100% and 78.9% respectively, and the CRR were 30.0% and 26.3% respectively, of which uMRD was reported in 20% of CLL/SLL and 16% of MCL patients. The median PFS of R/R MCL patients who had received treatment of BTK inhibitors before was 8.3 months. The PFS was not reached among BTK naïve R/R CLL/SLL and R/R MCL patients and BTK-treated R/R CLL/SLL patients. Poster 2: Title: Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients with NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 10048) The integrated analysis demonstrated that zurletrectinib had significant efficacy and good safety profile in pediatric and adolescent patients with NTRK+ solid tumors. Zurletrectinib also showed the potential to overcome the resistance to first generation TRK inhibitors. These findings support zurletrectinib is a better treatment option for NTRK+ pediatric and adolescent patients. As of Nov. 23, 2024, 18 patients in total were enrolled, including 8 pediatric patients and 10 adolescent patients. Among the 18 patients, 6 TRK inhibitor treatment-naïve patients with central lab confirmed NTRK+ were efficacy evaluable. The confirmed ORR assessed by IRC was 100%. All patients achieved partial response (PR) at the first tumor assessment and maintained the remission as of the cutoff date. Median time to response were 1.0 month in adolescent patients and 0.9 month in pediatric patients. It is worth noting that one pediatric patient who progressed on prior first-generation TRK inhibitor achieved complete response after receiving zurletrectinib. Poster 3: Title: Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 3112) In line with previously reported results, zurletrectinib continued to demonstrate a deep and durable responses in adult patients with NTRK+ advanced solid tumors with or without brain metastasis. Zurletrectinib was also well-tolerated and showed favorable safety profile in adult patients with various tumor types. As of Nov. 23, 2024, a total of 49 TRK inhibitor naïve adult patients were evaluable for efficacy representing 12 different solid tumor types. Among the efficacy population, the distribution of NTRK1, NTRK2 and NTRK3 fusions was 53.1%, 2.0% and 44.9% respectively. The confirmed ORR by IRC was 83.7%, with CR of 10.2%. Median duration of response (DOR) and median progression-free survival (PFS) by IRC were not reached. The DOR rate and PFS rate by IRC at 12 months was 92.0% and 90.5% respectively. Two of the three patients who had brain metastasis at the baseline achieved intracerebral ORR, which is consistent with the good brain penetration and strong intracranial activity of zurletrectinib. The 2025 ASCO Annual Meeting is held from May 30 to June 3, 2025 in Chicago, U.S. The ASCO annual meeting is the most important and professional academic event in the global oncology field, which showcases the international cutting-edge clinical oncology research results and tumor treatment technologies. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View source version on CONTACT: Media Chunhua Lu 86-10-66609879 [email protected] 86-10-66609999 [email protected] KEYWORD: CHINA ASIA PACIFIC INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS SOURCE: InnoCare Pharma Copyright Business Wire 2025. PUB: 06/01/2025 08:30 PM/DISC: 06/01/2025 08:31 PM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store